AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal

CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform

Biocon Biologics gets credit boost from S&P, outlook stable

The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’

Shilpa Medicare & mAbTree Biologics win FDA nod for rare blood cancer therapy

The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options

Mabtech & Sai Life Sciences launch strategic collab to revolutionize immunology research

EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time

Thyrocare posts strong Q3FY26 results: revenue up 18%, PAT soars 47%

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year

Moderna teams up with Recordati to commercialize rare disease therapy

AstraZeneca pledges $15 billion investment in China through 2030

UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."

BioMed X launches groundbreaking AI-driven diabetes research in Barbados

With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease

Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth

Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model